Accumulating evidence has shown that functional recoveries in various kinds of animal models of neurodegenerative diseases can be achieved by grafting fetal neurons into the brain. On the basis of these successful results, clinical trials are under way to determine whether human fetal mesencephalic 
Introduction
To date, numerous studies have shown that grafting fetal neuronal cells into the brain may hold great poten tial for a therapeutic approach to ameliorate human neurodegenerative diseases.1 Neural implantation, how ever, has yet to be considered as an optimal therapeutic strategy because several problems remain unresolved. Many of the difficulties of using fetal neurons as donor material are practical problems, including how to obtain sufficient numbers of viable cells of the desired phenotype, how to enhance their survival and neurite extension following implantation, and how to ensure histo compatibility between the donor and recipient. Because of these problems, alternative sources of donor ma terials, such as autologous adrenal medullary cells, have also been used but with limited application to intra cerebral grafting.2,3 Following implantation in the human parkinsonian brain, adrenal medullary cells exhibit poor survival. [4] [5] [6] Although still at the stage of animal exper imentation, genetic manipulation of autologous non neural cells such as primary fibroblasts7 and myoblasts8 is a new approach that may serve to supplement deficient substances within the damaged or diseased brain. Such genetically modified cells have been shown to deliver biologically active transgenes within the adult mammalian brain, including trophic factors9-12 and transmitter-specific enzymes,13-16 yet these cells are unable to replace lost neuronal populations or provide synpatic inputs to deafferentated neurons. Thus, it may still be better to use neuronal tissue for intracerebral grafting because anatomical and physiological reconstruction of damaged neural circuits, an important requirement for functional recovery, can only be achieved with such tissue. 17, 18 In addition, recent data reveal that certain gene transfer systems are able to introduce functional genetic infor mation into mature non-mitotic neurons, both in vitro and in vivo. verts tyrosine to L-DOPA which is the precursor to dopamine with the help of pterin cofactor. These geneti cally manipulated fibroblasts expressing TH minigene were implanted into the striatum of 6-hydroxydopamione (6-OHDA) rat model of Parkinson's disease to investigate its possible use as a donor material (Fig 1) . In vitro studies demonstrated that genetically manipulated NRK cells produced and secreted L-DOPA only when tetra hydrobiopterin (BH4) was added to the culture medium because of the absence of de novo synthesis of BH4 in these cells. Dopamine was not produced due to the absence of aromatic L-amino acid decarboxylase activity in the cells. Expression of TH transgene was preserved well when transplanted into the host striatum. L-DOPA was not released spontaneously from the implanted cells and behavioral amelioration of 6-OHDA rat was not achieved by the grafting of those cells. The failure to detect L-DOPA in vivo was possibly due to the low level of BH4 in the host striatum. Implanted fibroblasts trans fected with TH cDNA were able to secrete L-DOPA and apomorphine-induced rotating behavior was ameliorated when BH4 was added exogenously to the host brain. Findings contradictory to ours were reported by other groups.7,14 They observed functional recovery of 6-OHDA rats in the absence of BH4 administration following implantation of TH cDNA transfected fibroblasts, which can secrete L-DOPA in vitro only when BH4 was sup plemented exogenously. It is still unclear why the results are inconsistent among the investigators. It seems unlikely that host BH4 in the surrounding striatal tissue activate the TH molecules in the transplanted fibroblasts, because pterin cofactor necessary for tyrosine hydroxylation is not normally present at a saturating level in vivo and the amount of BH4 decreases markedly in the 6-OHDA rat striatum.
Another strategy used to examine the feasibility as a donor material of genetically manipulated non-neuronal cells involved the grafting of (3-nerve growth factor (NGF) cDNA transfected fibroblasts into the brain of Alzheimer's model.9-11 Fimbria-fornix is the pathway connecting cholinergic neurons of the basal forebrain to the target in the hippocampus. Cholinergic neurons are degenerated due to the loss of NGF support after the transection of fimbria-fornix. In this Alzheimer's model, NGF trans fected fibroblasts were grafted to determine whether these NGF producing and secreting non-neuronal cells could rescue the host dying neurons. These grafts were able to prevent the loss of choline acetyltransferase activity following lesions of the fimbria-fornix.
At the initial stage of the experiments, replicating non-neuronal cells such as skin fibroblasts are considered to be more available donor material for the genetic modification and grafting than non-mitotic neuronal cells, because replicating cells are susceptible to genetic alter ation using standard gene transfer techniques requiring mitotically active recipient cells. In order to obtain a stable expression of transgene, insertion of the transgene into the genome of host cells is mandatory. Many studies have been done using immortalized non-neuronal cells as donor material and retrovirus vector system as gene transfer technique for genetic modification and grafting.26 This strategy, however, has several problems to be solved in order to apply as a clinical treatment. A major con cern regarding this strategy is that non-neuronal cells is limited in the extent to which they can functionally integrate into the host neuronal circuitry. They can deliver key neurotransmitters or trophic factors through release and diffusion to surrounding host brain regardless of physiological requirements. Application of this method is restricted to some diseases that do not require the reconstruction of neural circuits for the functional recov ery, such as Parkinson's disease. It is still unclear whether or not synaptic connection between donor and host is necessary requirement for the host better functional restitution and the donor survival even in Parkinson's disease. Second concerns down regulation or shut down of transgene expression in the implanted genetically modified fibroblasts. As reported recently, retrovirus infected primary cells expressing reporter genes under the control of either constitutive or inducible promoters (e.g. retroviral 5' long terminal repeat, human inter mediate early cytomegalovirus) are unable to maintain reporter gene expression for extended period in vivo.27 The use of a housekeeping promoter (e. g. dihydrofolate reductase gene promoter), however, does permit con tinued foreign gene expression following grafting.27 In tissue culture, the choice of the promoter is not crucial for long-term expression of transgene.27 Therefore, in future studies we will have to give careful consideration to the selection of a promoter for the in vivo expression of transgene among genetically modified cells.
Grafting of Genetically Manipulated Neuronal Cells into Brain
Many investigators have argued that in some cases the anatomical and physiological reconstruction of compro mised neuronal circuits might be necessary requirements for the behavioral amelioration. Figure 2 shows the schema of the ideal neural transplantation therapy. Only neuronal cells with extensive axon growth can provide the anatomical and physiological reconstruction of neural circuits. To implement repair in situ, migratory capabili ties might also be necessary to allow donor cells to reach positions throughout an affected area without excessive surgical trauma.
Kordower et al28 reported recently an autopsy case of parkinsonian patient implanted with human fetal dopa Fig axonal growth.
Future Direction of "Graft-gene Therapy" Using Neuronal Cells
As mentioned above, CNS stem cells from the early embryo may have a number of important advantages as donor material for the "graft-gene therapy". It is, how ever, difficult to obtain human stem cells from the early embryo as desired. Practical problems associated with using human fetal tissue include the limited availability of donor tissue and the difficulty of scheduling the time required for proper screening of the donor tissue. One solution might be use CNS stem cells from other species if the immunological rejection can be controlled. It is advantageous to use the CNS stem cells of transgenic animals altered as desired by genetic engineering tech niques. A candidate for donor-offering animal might be a pig because of the acceptable size and availability.
Transgenic pig which carries the human gene for decay accelerating factor (DAF) is now available for organ transplantation.40 DAF is a regulatory membrane glyco protein for complement which mediates the hyperacute rejection reaction. It might be possible to alter the CNS stem cells to express key neuronal function by using transgenic animal techniques.
We predict that the bioartificial-, substitutional-, and neuronal-donor material is ideal for "graft-gene therapy" . Neuronal phenotype of donor cells is mandatory for the reconstruction of damaged neural circuits . To avoid the practical issue, genetic manipulation and grafting of xenogeneic cells are the solution. Thus, grafting of CNS stem cells from transgenic animals might be one of the powerful strategy toward "graft-gene therapy". 
